Mont Sorcier Iron Vanadium Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2025
0mins
Source: Globenewswire
Project Update: Chibougamau Independent Mines Inc. and Globex Mining Enterprises Inc. provided an update on the Mont Sorcier iron vanadium deposit, highlighting ongoing metallurgical tests aimed at producing high-grade iron concentrate with over 67% iron purity.
Feasibility Study: The companies are working towards a Bankable Feasibility Study (BFS) expected to be completed by Q1 2026, which will detail the project's potential based on previous assessments indicating a net present value of US$1.6 billion.
Analyst Views on CERT
Wall Street analysts forecast CERT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERT is 12.11 USD with a low forecast of 9.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 10.110
Low
9.00
Averages
12.11
High
16.00
Current: 10.110
Low
9.00
Averages
12.11
High
16.00
About CERT
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
